Therapeutic innovations, diminishing returns, and control rate preservation.
Kent
David M
DM
Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA 02111, USA. dkent1@tuftsmedicalcenter.org
Trikalinos
Thomas A
TA
D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D002317:Cardiovascular Agents / Q000627:therapeutic use; D000077144:Clopidogrel; D003937:Diagnosis, Differential; D004562:Electrocardiography; D019317:Evidence-Based Medicine; D006801:Humans; D007391:International Cooperation; D008790:Metoprolol / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D013300:Streptokinase / Q000627:therapeutic use; D013812:Therapeutics / Q000191:economics / Q000706:statistics & numerical data / Q000639:trends; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D014336:Troponin / Q000097:blood
D015415:Biomarkers; D002317:Cardiovascular Agents; D014336:Troponin; D000077144:Clopidogrel; D013300:Streptokinase; D008790:Metoprolol; D013988:Ticlopidine